Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; colloidal anhydrous silica; xanthan gum; sucrose; sodium benzoate; allura red ac; sodium citrate dihydrate; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 26.23 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; xanthan gum; sucrose; sodium citrate dihydrate; colloidal anhydrous silica; sodium benzoate; allura red ac; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 392.3 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - karlor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. karlor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of karlor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 26.86 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg; cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg - capsule - 250 mg - active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide